Mount Sinai Health System, based in New York City, will adopt an artificial intelligence-powered platform from SOPHiA GENETICS to expand its cancer research and genomic testing capabilities.
The health system plans to use the SOPHiA DDM Platform to strengthen next-generation sequencing for both blood cancers and solid tumors, supporting care for more than 4,000 oncology patients annually. Mount Sinai is a National Cancer Institute-designated comprehensive cancer center.
The platform is designed to detect and interpret complex genomic variants while streamlining laboratory workflows, reducing manual analysis time and consolidating multiple steps in the testing process, according to an April 16 news release.
Mount Sinai’s molecular pathology team will use the technology to analyze genomic data at scale and improve operational efficiency.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
